Cagrilintide-Semaglutide Improved HbA1c More Than Semaglutide in T2DM Tags hBA1c GLP-1 agonists SGLT-2 Inhibitor Read more about Cagrilintide-Semaglutide Improved HbA1c More Than Semaglutide in T2DM
Cardiovascular Outcomes Were Similar Between SGLT2 and DPP-4 Inhibitors in RA Tags Coronary artery disease DPP-4 inhibitors Rheumatoid Arthritis (RA) SGLT-2 Inhibitor Read more about Cardiovascular Outcomes Were Similar Between SGLT2 and DPP-4 Inhibitors in RA
Adjunctive Dapagliflozin Demonstrated Higher TIR Than Acarbose in T1DM Tags α-Glucosidase inhibitors SGLT-2 Inhibitor Continuous glucose monitoring (CGM) Read more about Adjunctive Dapagliflozin Demonstrated Higher TIR Than Acarbose in T1DM
SGLT2 Inhibitors Lowered Liver Enzymes More Than GLP-1 RAs Tags GLP-1 agonists SGLT-2 Inhibitor Read more about SGLT2 Inhibitors Lowered Liver Enzymes More Than GLP-1 RAs
Empagliflozin Improved Insulin Resistance More Than Sitagliptin Tags SGLT-2 Inhibitor Read more about Empagliflozin Improved Insulin Resistance More Than Sitagliptin
Experts Endorsed SGLT2i Before GLP-1 RA in CKD and T2DM Tags CKD Diabetic Nephropathy GLP-1 agonists SGLT-2 Inhibitor Read more about Experts Endorsed SGLT2i Before GLP-1 RA in CKD and T2DM
SGLT2 Inhibitors Were Linked to Lower Epilepsy Risk in T2DM Tags DPP-4 inhibitors SGLT-2 Inhibitor Read more about SGLT2 Inhibitors Were Linked to Lower Epilepsy Risk in T2DM
Finerenone Triple Therapy Slowed eGFR Decline in DKD Tags Diabetic Nephropathy SGLT-2 Inhibitor Read more about Finerenone Triple Therapy Slowed eGFR Decline in DKD
SGLT2 Inhibitors Showed Sustained Weight Reduction in PTDM Tags SGLT-2 Inhibitor hBA1c Read more about SGLT2 Inhibitors Showed Sustained Weight Reduction in PTDM
Canagliflozin Renal Benefits Were Similar Across 100 mg and 300 mg Doses Tags SGLT-2 Inhibitor Read more about Canagliflozin Renal Benefits Were Similar Across 100 mg and 300 mg Doses